Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International, inVentiv Health Collaborate on Biosimilars Development

NEW YORK (GenomeWeb News) – Proteomics International recently announced an agreement with inVentiv Health Clinical aimed at the development of biosimilars.

As part of the deal, Perth, Australia-based Proteomics International's services aimed at structural characterization and quality control testing of proposed and referenced products will be combined with inVentiv's bioanalytical capabilities.

The New Jersey-based firm provides drug development services.

According to Proteomics International, the deal "offers developers the ability to seamlessly transition from characterization to clinical trials, thereby streamlining the process and providing a competitive advantage in the race to market."

The company, founded in 2001, operates three business units. The diagnostics unit is focused on biomarker discovery and commercialization; the therapeutics unit concentrates on drug discovery of peptide medicines; and the analytics unit is a contract research organization that provides services to the biosimilars space.

Financial and other terms of the deal were not disclosed.

"This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment," Proteomics International Managing Director Richard Lipscombe said in a statement.